Revolution Medicines, Inc. , a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers.
Revolution Medicines stock last closed at $36.76, up 1.55% from the previous day, and has decreased 0.16% in one year. It has overperformed other stocks in the Biotechnology industry by 0.78 percentage points. Revolution Medicines stock is currently +26.02% from its 52-week low of $29.17, and -41.09% from its 52-week high of $62.40.
There are currently 185.91M RVMD shares outstanding. The market cap of RVMD is $6.83B. In the past 24 hours, 1.27M RVMD shares were traded.
How to Buy Revolution Medicines Stock
Wondering how to invest in Revolution Medicines stock? Here's how.
Figure out where to buy Revolution Medicines stock: You need to choose an online brokerage, but don't worry - we've sifted through dozens of online brokerages and apps to help you figure out where to buy Revolution Medicines stock.
Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
Deposit funds into your brokerage account: Pick your payment method and add your details.
Evaluate Revolution Medicines stock: The Revolution Medicines ticker symbol is RVMD. Is Revolution Medicines stock a good investment? Should you buy shares of RVMD? How do RVMD's underlying business fundamentals look? Do top analysts think Revolution Medicines is a good buy? Why has RVMD's stock price moved recently? (Hint: Our stock market analysis website can help you decide if RVMD is a good stock to buy).
Place your RVMD trade: Decide if you will purchase RVMD shares at the current market price or use a limit order to purchase RVMD shares at a particular price.
Track your investment in RVMD: Create a watchlist to watch your investment in Revolution Medicines stock.
Step 1: Figure out where to buy Revolution Medicines stock
You need an online brokerage account to access the NASDAQ market and buy RVMD stock.
A brokerage account is an investment account that enables you to buy and sell a variety of investments, including stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. Here's why:
You can invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
Access to global markets: From Technology to Industrials, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top stock exchanges.
Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open your brokerage account
Now that you've picked the right brokerage, you'll need to fill out some personal details so you can buy RVMD today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Revolution Medicines stock
After you have decided on the best place to buy Revolution Medicines stock, it's crucial to analyze their stock prior to buying, so you can wrap your head around the risk as well as the opportunity.
Revolution Medicines quick stats
RVMD Price
$36.76
1w %
9.18%
1y %
-0.16%
5y %
59.83%
P/E
-10.27x
P/B
3.02x
P/S
N/A
PEG
N/A
Revenue
$0.00
Earnings
-$600.09M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$6.83B
Next Earnings
May 6, 2025
Next Dividend
N/A
Revolution Medicines Due Diligence Score
WallStreetZen was designed to help part-time investors perform more in-depth fundamental analysis in less time.
There are more short-term assets than short-term liabilities on the RVMD balance sheet.
RVMD has a low debt to equity ratio of 0.13.
RVMD has $2.29B in cash and short term investments. This is sufficient to cover its annual cash burn of $567.74M.
RVMD has cash burn of 567744000. It has enough cash and short-term investments to cover this for at least one year.
There are more short-term assets than long-term liabilities on the RVMD balance sheet.
Total RVMD debt is lower than 5 years ago, relative to shareholder equity.
Is Revolution Medicines stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 10 Equities analysts who research RVMD, the consensus analyst rating on Revolution Medicines is a Strong Buy
It's important to keep in mind that analyst forecasts are not recommendations, nor are they financial advice.
Most Recent RVMD Analyst Ratings
Michael Schmidt, a top 31% analyst from Guggenheim maintains RVMD with a strong buy rating and raises their RVMD price target from $82.00 to $87.00, on Dec 3, 2024.
Guggenheim's Michael Schmidt raised their price target on Revolution Medicines (NASDAQ: RVMD) by 6.1% from $82 to $87 on 2024/12/03. The analyst maintained their Strong Buy rating on the stock.
Schmidt attributed their price target hike to increased odds of success assumptions in second-line non-small cell lung cancer after Revolution Medicines provided a clinical data update on its RAS inhibitor pipeline that Guggenheim characterized as "generally positive."
The update further de-risks the company's clinical development plans in PDAC, NSCLC, and CRC, the analyst said.
Eric Joseph, a bottom 4% analyst from JP Morgan maintains RVMD with a strong buy rating and raises their RVMD price target from $63.00 to $71.00, on Dec 3, 2024.
Joseph Catanzaro, a bottom 2% analyst from Piper Sandler maintains RVMD with a strong buy rating and raises their RVMD price target from $57.00 to $70.00, on Nov 7, 2024.
Michael Schmitz, a top 30% analyst from Guggenheim maintains RVMD with a strong buy rating and raises their RVMD price target from $72.00 to $82.00, on Oct 28, 2024.
Jay Olson, a top 8% analyst from Oppenheimer maintains RVMD with a buy rating and raises their RVMD price target from $55.00 to $60.00, on Oct 28, 2024.
Last year, RVMD revenue was $0.00. Over the last five year, RVMD's revenue has gone up by -100% per year. This was slower than the Biotechnology industry average of 44.43%.
No, Revolution Medicines doesn't provide an income stream by paying out dividends.
RVMD Social Trading Data
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your RVMD trade
There are two primary order types:
Market order: A market order is an order to buy or sell a stock at the best available price. Market orders are mostly fine for most investors.
Limit order: A limit order enables you to buy or sell a stock at a specific price (or better). If you want to be sure you're buying or selling at a given dollar amount limit, use a limit order.
Hit the Open button and your broker will place the order.
If you want additional help buying stocks on eToro, click the helpful video below:
How much does it cost to buy one Revolution Medicines share?
As of Apr 17, 2025, it costs $36.76 to buy one share of Revolution Medicines stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.272 shares of RVMD.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.